Featured Articles

1. Efficiency Is The New Normal 10/11/2024

   Despite groundbreaking innovations, biopharmaceutical companies have struggled to keep pace with capital markets, underscoring the importance of not only scientific innovation but also the need for efficient strategies to drive value growth.

2. Leading Through Adversity: How Putting People First Drives Success 10/8/2024

   In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO of Melinta Therapeutics, describes the challenges, actions, and experiences she faced as a new CEO.

3. AI, PoS, And ROI: An alphabet Soup Of 21st Century Drug Development 10/4/2024

   Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

4. The Benefits And Risks Of An LLC Business Model In Biotech 10/3/2024

   An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment and return. However, it won't work for every company, as Abbas Kazimi, chief business officer at Nimbus Therapeutics, explains.

5. DPHARM 2024 Highlights ClinOps Innovations That Address Cost, Complexity, & Capabilities 10/1/2024

   The 14th annual DPHARM conference included sessions ranging from the ROI of DCTs to how and where to innovate in a resource-constrained environment. In this article, we give some of the highlights from this informative annual event.

6. Annovis Bio: Against The Grain In Alzheimer's Disease 10/1/2024

   From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape. 

7. New Leadership At The Cancer Research Institute 9/27/2024

   Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.

8. A Supply-Chain Woman Of Iran 9/23/2024

   Arezou Mehrabi has a spellbinding supply-chain case study. It transpired, of all places, in Iran. It includes major challenges in outsourcing manufacturing to a partner CDMO for a top-ten pharma (Sanofi, to be exact). Our protagonist is a woman who took leadership within a male-dominated workplace, country, and entire region. 

9. Where Are They Now? Carisma Therapeutics 9/22/2024

   In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.

10. Thriving On Ambiguity: What I've Learned Leading Rare Disease Teams 9/19/2024

    Melissa Leichter, a Novo Nordisk executive, describes the distinct skills and mindset needed to succeed in bringing rare disease treatments to market.